Atrium Therapeutics Inc 's

• RNA's Stock Performance relative to its Competitors

Centessa Pharmaceuticals Plc Share Performance +0.80% Over The Past 5 Days

Centessa Pharmaceuticals Plc Profile Centessa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the discovery and development of innovative medicines. Their business model centers around leveraging a decentralized approach, with multiple subsidiary companies working autonomously to accelerate the research and development of potential therapeutics across various disease areas. By bringing together diverse expertise and resources, Centessa aims to efficiently advance breakthrough therapies and deliver impactful solutions to patients in need. More about Centessa Pharmaceuticals Plc's Market Share

Igm Biosciences Inc Share Performance -85.44% One Year

Igm Biosciences Inc Profile Igm Biosciences Inc's business model focuses on the discovery and development of engineered Immunoglobulin M (IgM) antibodies to treat various diseases, primarily cancer. More about Igm Biosciences Inc 's Market Share

Ionis Pharmaceuticals Inc Share Performance +9.89% 30 Days

Ionis Pharmaceuticals Inc Profile Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success. More about Ionis Pharmaceuticals Inc 's Market Share

Kyntra Bio Inc Share Performance +15.53% 30 Days

Kyntra Bio Inc Profile The company conducts preclinical development and clinical trials for its product candidates. More about Kyntra Bio Inc 's Market Share

Mirum Pharmaceuticals Inc Share Performance -5.98% 30 Days

Mirum Pharmaceuticals Inc Profile Mirum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing innovative therapies for patients with rare liver diseases. More about Mirum Pharmaceuticals Inc 's Market Share

Sources: Atrium Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, August 31, 2026 7:03 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Atrium Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.